We are now halfway through 2025, and it’s not too late to highlight the practices and trends that are shaping and will continue to shape the biopharma landscape this year. In 2024, we navigated the 4 biopharma trends that exerted vehement force in the industry and shaped the course of healthcare practices. Last year, the…
Shots:
XtalPi has entered into a strategic collaboration with DoveTree Medicines to identify novel therapeutics across oncology, immunology, inflammation, neurology, & metabolic diseases, leveraging XtalPi's de novo drug discovery platform
As per the deal, DoveTree will gain exclusive global rights to develop & commercialize multiple therapeutics from the collaboration, in exchange for a $51M upfront,…
Discovery & Development Summit Asia 2025 is Global Engage’s inaugural platform that brings together the Drug Discovery & Development, Nucleic Acid Therapeutics and Precision Medicine congresses. This summit allows the exploration of the full spectrum of therapeutic innovation, from early-stage discovery to clinical translation and commercialization. Attendees will gain insights into assay development, screening technologies,…
Shots:
Precision medicine holds a promising foothold in addressing unmet healthcare needs and bridging the gaps in care accessibility and high treatment costs
Defying the one-size-fits-all model, personalized medicine offers therapies tailored to an individual’s physiology, lifestyle, and environment
With this article, let’s capture the intricacies of precision medicine by navigating the benefits, challenges, progress,…
Shots:
The biopharma industry faces several challenges, including digital transformation, regulatory compliance, and managing large volumes of data
Intelligent automation plays a vital role in drug discovery, clinical trials, manufacturing, and commercialization, helping optimize operations and better meet customer needs
Astrix CEO Dale Curtis Jr. discusses the role of AI and machine learning in global…
Shots:
AI is widely used in drug discovery and clinical research to find innovative cures for several debilitating conditions with unmet healthcare needs
Most of the AI architecture employs deep learning that requires extensive training data sets to produce reliable predictive models
Today, at PharmaShots, we have Adityo Prakash, CEO of Verseon, addressing the challenges…
Shots:
Simon spoke about the enrollment of the first participant in Japan in the P-III (SCORPIO-PEP) study to evaluate the safety and efficacy of Ensitrelvir for the prevention of symptomatic SARS-CoV-2 infection
He mentioned how this study will supplement data from the pivotal SCORPIO-SR trial's P-III segment which showed ensitrelvir's effectiveness in treating mild-to-moderate COVID-19…
Shots:
With more than 50% of ongoing clinical trials worldwide in oncology domains, cancer remains one of the leading causes of death worldwide. Oncology companies are steadfastly looking for innovative therapies to cure both hematologic and solid tumor cancer
The global oncology drug market size in 2022 was valued at $185B and is forecasted to…
Shots:
Driven by the influx of life-changing innovations and technological advances, the pharmaceutical industry is forging ahead at a momentous pace. With the impelling Pharma 4.0, automation has now been embedded in various aspects of current business practices
Delving deeply into the importance of automation, primarily focusing on AI & ML, PharmaShots unveils its eight-step…
Shots:
Craig shared with our readers the preclinical study results of C101248 demonstrating its pharmacological activity and validation of the NETSseq platform as an effective method to interpret new therapeutic targets for Alzheimer’s disease
He also elaborated on how the combination of the NETSseq platform and C101248 will help in the identification and development of…

